vs
Quest Resource Holding Corp（QRHC）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Quest Resource Holding Corp的季度营收约是REGENXBIO Inc.的1.9倍（$58.9M vs $30.3M），Quest Resource Holding Corp净利率更高（-2.8% vs -221.3%，领先218.5%），REGENXBIO Inc.同比增速更快（43.0% vs -15.8%），Quest Resource Holding Corp自由现金流更多（$1.0M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -10.0%）
Quest Resource Holding Corp是北美地区的可持续发展及废弃物管理服务提供商，面向商业、工业及零售客户提供一体化废弃物回收、资源化利用解决方案，帮助企业减少废弃物排放、降低运营成本，达成既定环保目标。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
QRHC vs RGNX — 直观对比
营收规模更大
QRHC
是对方的1.9倍
$30.3M
营收增速更快
RGNX
高出58.8%
-15.8%
净利率更高
QRHC
高出218.5%
-221.3%
自由现金流更多
QRHC
多$53.8M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-10.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $58.9M | $30.3M |
| 净利润 | $-1.7M | $-67.1M |
| 毛利率 | 15.5% | — |
| 营业利润率 | 0.9% | -190.0% |
| 净利率 | -2.8% | -221.3% |
| 营收同比 | -15.8% | 43.0% |
| 净利润同比 | 82.6% | -31.2% |
| 每股收益（稀释后） | $-0.08 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收QRHCRGNX
| Q4 25 | $58.9M | $30.3M | ||
| Q3 25 | $63.3M | $29.7M | ||
| Q2 25 | $59.5M | $21.4M | ||
| Q1 25 | $68.4M | $89.0M | ||
| Q4 24 | $70.0M | $21.2M | ||
| Q3 24 | $72.8M | $24.2M | ||
| Q2 24 | $73.1M | $22.3M | ||
| Q1 24 | $72.7M | $15.6M |
净利润QRHCRGNX
| Q4 25 | $-1.7M | $-67.1M | ||
| Q3 25 | $-1.3M | $-61.9M | ||
| Q2 25 | $-2.0M | $-70.9M | ||
| Q1 25 | $-10.4M | $6.1M | ||
| Q4 24 | $-9.5M | $-51.2M | ||
| Q3 24 | $-3.4M | $-59.6M | ||
| Q2 24 | $-1.5M | $-53.0M | ||
| Q1 24 | $-655.0K | $-63.3M |
毛利率QRHCRGNX
| Q4 25 | 15.5% | — | ||
| Q3 25 | 18.1% | — | ||
| Q2 25 | 18.5% | — | ||
| Q1 25 | 16.0% | — | ||
| Q4 24 | 15.3% | 70.2% | ||
| Q3 24 | 16.1% | 48.8% | ||
| Q2 24 | 18.5% | 52.5% | ||
| Q1 24 | 19.3% | 72.6% |
营业利润率QRHCRGNX
| Q4 25 | 0.9% | -190.0% | ||
| Q3 25 | 1.7% | -176.3% | ||
| Q2 25 | 0.6% | -296.3% | ||
| Q1 25 | -11.9% | 13.6% | ||
| Q4 24 | -10.3% | -242.1% | ||
| Q3 24 | -1.3% | -256.6% | ||
| Q2 24 | 2.4% | -251.3% | ||
| Q1 24 | 2.6% | -408.8% |
净利率QRHCRGNX
| Q4 25 | -2.8% | -221.3% | ||
| Q3 25 | -2.1% | -208.3% | ||
| Q2 25 | -3.3% | -331.8% | ||
| Q1 25 | -15.2% | 6.8% | ||
| Q4 24 | -13.6% | -241.3% | ||
| Q3 24 | -4.7% | -246.3% | ||
| Q2 24 | -2.1% | -237.7% | ||
| Q1 24 | -0.9% | -405.4% |
每股收益（稀释后）QRHCRGNX
| Q4 25 | $-0.08 | $-1.30 | ||
| Q3 25 | $-0.06 | $-1.20 | ||
| Q2 25 | $-0.09 | $-1.38 | ||
| Q1 25 | $-0.50 | $0.12 | ||
| Q4 24 | $-0.47 | $-0.99 | ||
| Q3 24 | $-0.16 | $-1.17 | ||
| Q2 24 | $-0.07 | $-1.05 | ||
| Q1 24 | $-0.03 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.0M | $230.1M |
| 总债务越低越好 | $64.0M | — |
| 股东权益账面价值 | $40.5M | $102.7M |
| 总资产 | $145.6M | $453.0M |
| 负债/权益比越低杠杆越低 | 1.58× | — |
8季度趋势，按日历期对齐
现金及短期投资QRHCRGNX
| Q4 25 | $1.0M | $230.1M | ||
| Q3 25 | $1.1M | $274.2M | ||
| Q2 25 | $449.0K | $323.3M | ||
| Q1 25 | $1.4M | $267.9M | ||
| Q4 24 | $396.0K | $234.7M | ||
| Q3 24 | $1.1M | $255.5M | ||
| Q2 24 | $957.5K | $290.4M | ||
| Q1 24 | $581.1K | $338.7M |
总债务QRHCRGNX
| Q4 25 | $64.0M | — | ||
| Q3 25 | $65.4M | — | ||
| Q2 25 | $69.7M | — | ||
| Q1 25 | $74.1M | — | ||
| Q4 24 | $76.3M | — | ||
| Q3 24 | $71.9M | — | ||
| Q2 24 | $70.7M | — | ||
| Q1 24 | $68.5M | — |
股东权益QRHCRGNX
| Q4 25 | $40.5M | $102.7M | ||
| Q3 25 | $42.0M | $161.5M | ||
| Q2 25 | $42.9M | $213.7M | ||
| Q1 25 | $44.4M | $274.2M | ||
| Q4 24 | $54.2M | $259.7M | ||
| Q3 24 | $62.8M | $301.4M | ||
| Q2 24 | $65.6M | $348.3M | ||
| Q1 24 | $66.3M | $390.7M |
总资产QRHCRGNX
| Q4 25 | $145.6M | $453.0M | ||
| Q3 25 | $149.3M | $525.2M | ||
| Q2 25 | $153.1M | $581.0M | ||
| Q1 25 | $165.7M | $490.9M | ||
| Q4 24 | $175.6M | $466.0M | ||
| Q3 24 | $178.2M | $519.1M | ||
| Q2 24 | $181.8M | $569.4M | ||
| Q1 24 | $179.0M | $629.2M |
负债/权益比QRHCRGNX
| Q4 25 | 1.58× | — | ||
| Q3 25 | 1.56× | — | ||
| Q2 25 | 1.62× | — | ||
| Q1 25 | 1.67× | — | ||
| Q4 24 | 1.41× | — | ||
| Q3 24 | 1.15× | — | ||
| Q2 24 | 1.08× | — | ||
| Q1 24 | 1.03× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.1M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $1.0M | $-52.8M |
| 自由现金流率自由现金流/营收 | 1.7% | -174.0% |
| 资本支出强度资本支出/营收 | 0.1% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $9.3M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流QRHCRGNX
| Q4 25 | $1.1M | $-52.3M | ||
| Q3 25 | $5.7M | $-56.0M | ||
| Q2 25 | $3.9M | $-49.3M | ||
| Q1 25 | $-1.1M | $33.6M | ||
| Q4 24 | $-4.8M | $-31.6M | ||
| Q3 24 | $-475.0K | $-40.5M | ||
| Q2 24 | $808.0K | $-45.5M | ||
| Q1 24 | $-1.7M | $-55.5M |
自由现金流QRHCRGNX
| Q4 25 | $1.0M | $-52.8M | ||
| Q3 25 | $5.6M | $-56.5M | ||
| Q2 25 | $3.9M | $-49.7M | ||
| Q1 25 | $-1.2M | $32.6M | ||
| Q4 24 | $-5.2M | $-32.7M | ||
| Q3 24 | $-583.0K | $-40.9M | ||
| Q2 24 | $-1.4M | $-46.0M | ||
| Q1 24 | $-3.6M | $-56.0M |
自由现金流率QRHCRGNX
| Q4 25 | 1.7% | -174.0% | ||
| Q3 25 | 8.9% | -189.9% | ||
| Q2 25 | 6.5% | -232.8% | ||
| Q1 25 | -1.8% | 36.6% | ||
| Q4 24 | -7.4% | -154.2% | ||
| Q3 24 | -0.8% | -168.9% | ||
| Q2 24 | -2.0% | -206.2% | ||
| Q1 24 | -4.9% | -358.5% |
资本支出强度QRHCRGNX
| Q4 25 | 0.1% | 1.7% | ||
| Q3 25 | 0.0% | 1.7% | ||
| Q2 25 | 0.0% | 1.8% | ||
| Q1 25 | 0.2% | 1.2% | ||
| Q4 24 | 0.6% | 5.1% | ||
| Q3 24 | 0.1% | 1.3% | ||
| Q2 24 | 3.1% | 2.1% | ||
| Q1 24 | 2.6% | 3.6% |
现金转化率QRHCRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
QRHC
| Services | $55.8M | 95% |
| Product Sales And Other | $3.1M | 5% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
